UPDATE 1-Bristol hikes 2016 profit forecast after top drugs deliver
October 27, 2016 at 07:42 AM EDT
Oct 27 (Reuters) - Bristol-Myers Squibb Co, whose shares have plunged since its new Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after surprisingly strong quarterly sales of other leading medicines.
